ArticleClinical genitourinary cancer2014
The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group.
Article in Clinical genitourinary cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Pooled it
- Association of Pain With Mental and Physical Function in Patients With Chemotherapy-Induced Peripheral Neuropathy: A Secondary Analysis From Two Randomized Controlled Trials.Muscle & nerve · 2026Trial
- Excess Body Weight and Cancer-Related Fatigue, Systemic Inflammation, and Serum Lipids in Breast Cancer Survivors.Nutrition and cancer · 2021Trial
- Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- Article
- Article
- Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.Nature reviews. Urology · 2023Review
- Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors.Cancer medicine · 2023Article
- Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors.Head & neck · 2022Article
- Translation and validation of the Chinese version of the MD Anderson symptom inventory for measuring perioperative symptom burden in patients with gynecologic cancer.BMC women's health · 2021Article
- Understanding Treatment Tolerability in Older Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.Neuro-oncology practice · 2021Article
- Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery.Gynecologic oncology · 2021Article
- Longitudinal assessment of the impact of higher body mass index on cancer-related fatigue in patients with breast cancer receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Understanding Symptom Burden in Patients With Advanced Cancer Living in Rural Areas.Oncology nursing forum · 2019Article
- Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Review
- Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe MD Anderson Symptom Inventory (MDASI) is a psychometrically validated patient-reported outcome measure that assesses the severity and impact of multiple symptoms related to cancer and its treatment and has the potential to guide treatment specific to patients with prostate cancer. Although the original MDASI validation study encompassed various cancer types, the instrument's psychometric properties have not been examined in a large homogeneous sample of patients with prostate cancer. PATIENTS AND
methodsThis study involved secondary analysis of data from the nationwide multicenter Eastern Cooperative Oncology Group (ECOG) SOAPP (Symptom Outcomes and Practice Patterns) study, which enrolled patients from 38 ECOG-affiliated institutions, including 6 academic centers and 32 community clinics. Data were used to establish the psychometric properties of the MDASI in a subsample of 320 patients with prostate cancer. The instrument was administered twice, approximately 1 month apart.
resultsThe MDASI demonstrated good internal consistency and test-retest reliability (with Cronbach alphas of ≥ .84 and intraclass correlations of ≥ 0.76 for all subscales), strong ability to discriminate between clinically different patient groups (by performance status, tumor response, and disease stage), and high sensitivity in detecting symptom change (with respect to patient-reported quality of life [QOL] between the baseline and 1-month follow-up visits).
conclusionThe MDASI is a valid, reliable, and sensitive symptom-assessment instrument that can be used with confidence in descriptive and clinical studies of symptom status in patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.